Lannett’s Insulin Aspart Biosimilar Takes ‘Major Step’ Forward

Lannett’s Insulin Aspart On Track For Key Development Milestones After Positive Animal Study Results

 
• By Rosalind Rei
  
Laboratory worker writes on clipboard, with test-tube rack in the foreground
Lannett's Insulin Aspart Is A Major Pipeline Asset For the US Firm • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business